Patents by Inventor Silke Aigner
Silke Aigner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230151442Abstract: A lysis buffer comprising one non-ionic surfactant is provided which can be used as a one-step reagent of the preparation, storage, amplification, and/or detection of nucleic acids. Various embodiments of the lysis buffer of the invention comprise other substances that are compatible or useful in lysing cells, storing nucleic acids, amplifying nucleic acids, purifying nucleic acids, detecting nucleic acids, and/or other procedures for analysis of nucleic acids. Methods and kits based on the lysis buffer are also provided, including those for rapid lysis of cells and direct use of the resulting cell lysates in RT-PCR.Type: ApplicationFiled: April 1, 2021Publication date: May 18, 2023Applicant: Bayer AktiengesellschaftInventors: Stefan GOLZ, Holger SUMMER, Silke AIGNER, Heidrun ELLINGER-ZIEGELBAUER, Kirsten LEINEWEBER, Thomas MÜLLER
-
Publication number: 20170081418Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.Type: ApplicationFiled: June 18, 2016Publication date: March 23, 2017Inventors: Elmar KRAUS, Christoph BRUECHER, Benjamin DAELKEN, Steffen ZENG, Frank OSTERROTH, Christoph UHEREK, Silke AIGNER, Matthias GERMER, Gregor SCHULZ, Thomas HAEDER
-
Patent number: 9550831Abstract: The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.Type: GrantFiled: September 13, 2010Date of Patent: January 24, 2017Assignee: BIOTEST AGInventors: Silke Aigner, Matthias Germer, Frank Osterroth, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken, Gregor Schulz
-
Patent number: 9512226Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.Type: GrantFiled: September 13, 2010Date of Patent: December 6, 2016Assignee: BIOTEST AGInventors: Matthias Germer, Frank Osterroth, Silke Aigner, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken, Gregor Schulz
-
Patent number: 9446146Abstract: Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents.Type: GrantFiled: December 23, 2008Date of Patent: September 20, 2016Assignees: BIOTEST AG, IMMUNOGEN INC., Dana-Farber Cancer InstituteInventors: Benjamin Daelken, Christoph Uherek, Kenneth Anderson, Teru Hideshima, Christoph Bruecher, Frank Osterroth, Silke Aigner, Matthias Germer
-
Patent number: 9387261Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.Type: GrantFiled: December 23, 2008Date of Patent: July 12, 2016Assignees: BIOTEST AG, IMMUNOGEN INC.Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Matthias Germer, Gregor Schulz, Thomas Haeder
-
Publication number: 20160185854Abstract: Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.Type: ApplicationFiled: July 29, 2015Publication date: June 30, 2016Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Silke Aigner, Gregor Schulz, Christoph Uherek
-
Patent number: 9334325Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.Type: GrantFiled: September 13, 2010Date of Patent: May 10, 2016Assignee: BIOTEST AGInventors: Frank Osterroth, Silke Aigner, Matthias Germer, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken
-
Patent number: 9289509Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.Type: GrantFiled: May 5, 2010Date of Patent: March 22, 2016Assignees: Biotest AG, Immunogen Inc.Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng, Gregor Schulz
-
Patent number: 9221914Abstract: Disclosed is a human murine chimeric antibody targeting CD138 which substantially retains the antigen binding region of its murine counterpart. The engineered antibody displays improved binding affinities to the antigen and/or more homogenous binding to target cells relative to its murine counterpart. A constant region of the immunoglobulin heavy chain is preferably an IgG4 isotype constant region.Type: GrantFiled: December 23, 2008Date of Patent: December 29, 2015Assignee: BIOTEST AGInventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Gregor Schulz
-
Patent number: 9011864Abstract: Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.Type: GrantFiled: December 23, 2008Date of Patent: April 21, 2015Assignees: Biotest AG, Immunogen, Inc.Inventors: Gregor Schulz, Christoph Bruecher, Frank Osterroth, Steffen Zeng, Christoph Uherek, Silke Aigner, Benjamin Daelken, Markus Ruehle, Elmar Kraus
-
Publication number: 20110229465Abstract: The present invention provides pharmaceutical compositions and kits comprising an agent capable of activating CD4+CD25+ regulatory T cells and methotrexate, and methods of treatment and medical uses utilising the same.Type: ApplicationFiled: March 29, 2011Publication date: September 22, 2011Inventors: Frank Osterroth, Silke Aigner, Christoph Uherek, Andrea Wartenberg-Demand, Anatoly Rudnev, Michael Soldan, Christoph Bruecher, Benjamin Daelken, Chantal Zuber, Gregor Schulz, Niklas Czeloth
-
Publication number: 20110123554Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.Type: ApplicationFiled: May 5, 2010Publication date: May 26, 2011Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng
-
Publication number: 20110059082Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.Type: ApplicationFiled: September 13, 2010Publication date: March 10, 2011Inventors: Matthias Germer, Frank Osterroth, Silke Aigner, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken
-
Publication number: 20110059083Abstract: The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.Type: ApplicationFiled: September 13, 2010Publication date: March 10, 2011Inventors: SILKE AIGNER, MATTHIAS GERMER, FRANK OSTERROTH, CHRISTOPH UHEREK, ELMAR KRAUS, ANDREA WARTENBERG-DEMAND, DANIELE WOLF, SIBYLLE KAISER, JUERGEN LINDNER, CHRISTOPH BRUECHER, BENJAMIN DAELKEN
-
Publication number: 20110059084Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.Type: ApplicationFiled: September 13, 2010Publication date: March 10, 2011Inventors: FRANK OSTERROTH, SILKE AIGNER, MATTHIAS GERMER, CHRISTOPH UHEREK, ELMAR KRAUS, ANDREA WARTENBERG-DEMAND, DANIELE WOLF, SIBYLLE KAISER, JUERGEN LINDNER, CHRISTOPH BRUECHER, BENJAMIN DAELKEN
-
Publication number: 20090232810Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.Type: ApplicationFiled: December 23, 2008Publication date: September 17, 2009Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Matthias Germer
-
Publication number: 20090181038Abstract: Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and kits allow appropriate sequestration of non-target cells while maintaining a high degree of effectiveness of the immunoconjugates against target cells.Type: ApplicationFiled: December 23, 2008Publication date: July 16, 2009Inventors: Gregor Schulz, Christoph Bruecher, Frank Osterroth, Steffen Zeng, Christoph Uherek, Silke Aigner, Benjamin Daelken, Markus Ruehle, Elmar Kraus
-
Publication number: 20090175863Abstract: Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.Type: ApplicationFiled: December 23, 2008Publication date: July 9, 2009Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner